CUE · Cue Biopharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.69M | - | $2.15M | $2.95M | $421.0K | - | $3.34M | $2.66M | $1.72M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.90M | - | $4.75M | $7.91M | $8.55M | - | $9.38M | $9.53M | $10.20M | - |
| SG&A | $4.15M | - | $4.94M | $3.68M | $4.17M | - | $2.87M | $3.51M | $4.19M | - |
| Total Operating Expenses | $11.04M | - | $9.74M | $11.59M | $12.72M | - | $12.15M | $13.04M | $14.38M | - |
| D&A | $566.0K | - | $76.0K | $97.0K | $101.0K | - | $100.0K | $100.0K | $99.0K | - |
| Operating Income | ($5.35M) | - | ($7.59M) | ($8.63M) | ($12.30M) | - | ($8.81M) | ($10.38M) | ($12.67M) | - |
| Interest Expense | $100.0K | - | - | - | - | - | - | - | $33.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | $400.0K | - |
| Net Income | ($5.18M) | - | ($7.45M) | ($8.48M) | ($12.26M) | - | ($8.66M) | ($10.17M) | ($12.35M) | - |
| EPS - Basic | ($1.08) | - | ($2.10) | ($2.70) | ($5.10) | - | ($5.10) | ($6.00) | ($7.50) | - |
| EPS - Diluted | ($1.08) | - | ($2.10) | ($2.70) | ($5.10) | - | ($5.10) | ($6.00) | ($7.50) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.38M | $27.14M | $11.70M | $27.49M | $13.14M | $22.46M | $32.42M | $30.03M | $41.03M | $48.51M |
| Accounts Receivable | $5.35M | $5.55M | $387.0K | $532.0K | $0 | $945.0K | $3.15M | $1.85M | $1.40M | $1.70M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.33M | $3.95M | $2.35M | $3.63M | $3.78M | $2.82M | $6.47M | $3.91M | $3.92M | $3.50M |
| Current Assets | $26.39M | $36.98M | $25.82M | $30.84M | $15.93M | $25.14M | $37.26M | $33.90M | $44.67M | $51.45M |
| Total Assets | $30.88M | $42.21M | $31.64M | $40.71M | $22.25M | $32.19M | $44.81M | $42.33M | $53.95M | $61.53M |
| Current Liabilities | $7.39M | $13.49M | $15.52M | $19.25M | $15.50M | $13.69M | $16.79M | $16.46M | $18.09M | $17.08M |
| Long-term Debt | - | - | - | - | - | $0 | $1.33M | $2.29M | $3.24M | $4.20M |
| Total Liabilities | $9.27M | $15.78M | $18.40M | $22.55M | $15.67M | $14.69M | $19.44M | $20.71M | $23.91M | $24.45M |
| Stockholders' Equity | $21.61M | $26.43M | $13.25M | $18.16M | $6.58M | $17.50M | $25.37M | $21.62M | $30.04M | $37.09M |
| Retained Earnings | ($373.64M) | ($368.47M) | ($370.05M) | ($362.60M) | ($354.12M) | ($341.86M) | ($332.37M) | ($323.71M) | ($313.54M) | ($301.19M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($10.94M) | - | - | - | ($8.17M) | - | - | - | ($9.78M) | - |
| Investing Cash Flow | ($121.0K) | - | - | - | ($150.0K) | - | - | - | ($55.0K) | - |
| Financing Cash Flow | $306.0K | - | - | - | ($1.00M) | - | - | - | $2.35M | - |
| CapEx | $121.0K | - | - | - | $150.0K | - | - | - | $55.0K | - |
| Free Cash Flow | ($11.06M) | - | - | - | ($8.32M) | - | - | - | ($9.84M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -94.1% | - | -353.4% | -292.3% | -2921.4% | - | -264.2% | -390.6% | -737.8% | - |
| EBITDA margin | -84.2% | - | -349.9% | -289.0% | -2897.4% | - | -261.2% | -386.9% | -732.0% | - |
| Net margin | -91.1% | - | -346.6% | -287.1% | -2911.4% | - | -259.6% | -382.7% | -719.1% | - |
| Free cash flow margin | -194.6% | - | - | - | -1976.7% | - | - | - | -573.0% | - |
| FCF / Net income | 2.14 | - | - | - | 0.68 | - | - | - | 0.80 | - |
| R&D / Revenue | 121.3% | - | 221.2% | 267.8% | 2030.2% | - | 281.2% | 358.5% | 594.0% | - |
| SG&A / Revenue | 73.0% | - | 229.8% | 124.5% | 991.2% | - | 85.9% | 132.1% | 243.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -16.8% | - | -23.5% | -20.8% | -55.1% | - | -19.3% | -24.0% | -22.9% | - |
| Return on equity | -24.0% | - | -56.2% | -46.7% | -186.3% | - | -34.1% | -47.0% | -41.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | -30.1% | - |
| Liquidity | ||||||||||
| Current ratio | 3.57 | 2.74 | 1.66 | 1.60 | 1.03 | 1.84 | 2.22 | 2.06 | 2.47 | 3.01 |
| Quick ratio | 3.57 | 2.74 | 1.66 | 1.60 | 1.03 | 1.84 | 2.22 | 2.06 | 2.47 | 3.01 |
| Cash ratio | 2.22 | 2.01 | 0.75 | 1.43 | 0.85 | 1.64 | 1.93 | 1.82 | 2.27 | 2.84 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | 0.00 | 0.05 | 0.11 | 0.11 | 0.11 |
| Debt / Assets | - | - | - | - | - | 0.00 | 0.03 | 0.05 | 0.06 | 0.07 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -53.5x | - | - | - | - | - | - | - | -383.9x | - |
| Equity multiplier | 1.43 | 1.60 | 2.39 | 2.24 | 3.38 | 1.84 | 1.77 | 1.96 | 1.80 | 1.66 |
| Liabilities / Assets | 0.30 | 0.37 | 0.58 | 0.55 | 0.70 | 0.46 | 0.43 | 0.49 | 0.44 | 0.40 |
| Efficiency | ||||||||||
| Asset turnover | 0.18 | - | 0.07 | 0.07 | 0.02 | - | 0.07 | 0.06 | 0.03 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 343d | - | 66d | 66d | 0d | - | 345d | 254d | 298d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.5x | - | 164.3x | 107.6x | 308.4x | - | 45.9x | 86.3x | 93.4x | - |
| P / S | 5.8x | - | 1012.4x | 661.2x | 4820.4x | - | 348.7x | 702.2x | 1633.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 1250.6% | - | -35.6% | 11.1% | -75.5% | - | 58.9% | 92.3% | 818.2% | - |
| Revenue CAGR (3y) | 212.1% | - | 216.2% | 384.3% | -25.1% | - | 11.7% | -1.0% | 3.4% | - |
| Revenue CAGR (5y) | 29.6% | - | 25.0% | 22.4% | -14.1% | - | 27.7% | 20.3% | 35.9% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 56.5% | - | 13.8% | 16.8% | 2.9% | - | 22.8% | 23.2% | 5.3% | - |
| Net income growth (YoY) | 57.8% | - | 14.0% | 16.6% | 0.7% | - | 21.3% | 22.9% | 5.8% | - |
| EPS growth (YoY) | 78.8% | - | 58.8% | 55.0% | 32.0% | - | -2025.0% | -1521.6% | -2486.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -32.9% | - | - | - | 15.4% | - | - | - | 9.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 228.4% | 51.0% | -47.8% | -16.0% | -78.1% | -52.8% | -40.5% | -53.0% | -45.4% | -43.5% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Cue Biopharma against the 5 most active filers in the same SIC group.